Literature DB >> 7582524

Ca(2+)-dependent and -independent mechanism of cyclic-AMP reduction: mediation by bradykinin B2 receptors.

H Sipma1, A den Hertog, A Nelemans.   

Abstract

1. Bradykinin caused a transient reduction of about 25% in the cyclic AMP level in forskolin prestimulated DDT1 MF-2 smooth muscle cells (IC50: 36.4 +/- 4.9 nM) and a pronounced, sustained inhibition (40%) of the isoprenaline-stimulated cyclic AMP level (IC50: 37.5 +/- 1.1 nM). 2. The Ca2+ ionophore, ionomycin, mimicked both the bradykinin-induced transient reduction in the forskolin-stimulated cyclic AMP level and the sustained reduction in the isoprenaline-stimulated cyclic AMP level. 3. The Ca(2+)-dependent effect on cyclic AMP induced by bradykinin was mediated solely by Ca2+ release from internal stores, since inhibition of Ca2+ entry with LaCl3 did not reduce the response to bradykinin. 4. The involvement of calmodulin-dependent enzyme activities, protein kinase C or an inhibitory GTP binding protein in the bradykinin-induced responses was excluded since a calmodulin inhibitor, calmidazolium, a PKC inhibitor, staurosporine and pertussis toxin, respectively did not affect the decline in the cyclic AMP level. 5. Bradykinin enhanced the rate of cyclic AMP breakdown in intact cells, which effect was not mimicked by ionomycin. This suggested a Ca(2+)-independent activation of phosphodiesterase activity by bradykinin in DDT1 MF-2 cells. 6. The bradykinin B1 receptor agonist, desArg9-bradykinin, did not affect cyclic AMP formation in isoprenaline prestimulated cells, while the bradykinin B2 receptor antagonists, Hoe 140 (D-Arg[Hyp3, Thi5, D-Tic7, Oic8]-BK) and D-Arg[Hyp3, Thi5,8, D-Phe7]-BK completely abolished the bradykinin response in both forskolin and isoprenaline prestimulated cells. 7. Bradykinin caused an increase in intracellular Ca2+, which was antagonized by the bradykinin B2 receptor antagonists, Hoe 140 and D-Arg[Hyp3, Thi5,8, D-Phe7]-BK. The bradykinin B2 receptor agonist,desArg9-bradykinin, did not evoke a rise in cytoplasmic Ca2 .8. It is concluded, that stimulation of bradykinin B2 receptors causes a reduction in cellular cyclic AMP in DDT1, MF-2 cells. This decline in cyclic AMP is partly mediated by a Ca2+/calmodulin independent activation of phosphodiesterase activity. The increase in [Ca2+], mediated by bradykinin B2 receptors inhibited forskolin- and isoprenaline-activated adenylyl cyclase differently, most likely by interfering with different components of the adenylyl cyclase signalling pathway.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7582524      PMCID: PMC1909031          DOI: 10.1111/j.1476-5381.1995.tb15901.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  Identification of the phosphodiesterase regulated by muscarinic cholinergic receptors of 1321N1 human astrocytoma cells.

Authors:  L I Tanner; T K Harden; J N Wells; M W Martin
Journal:  Mol Pharmacol       Date:  1986-05       Impact factor: 4.436

2.  P2-purinergic receptors are coupled to two signal transduction systems leading to inhibition of cAMP generation and to production of inositol trisphosphate in rat hepatocytes.

Authors:  F Okajima; Y Tokumitsu; Y Kondo; M Ui
Journal:  J Biol Chem       Date:  1987-10-05       Impact factor: 5.157

3.  P2-purinoceptor-mediated membrane currents in DDT1 MF-2 smooth muscle cells.

Authors:  A Molleman; A Nelemans; A Den Hertog
Journal:  Eur J Pharmacol       Date:  1989-10-04       Impact factor: 4.432

4.  Comparison of the calmodulin antagonists compound 48/80 and calmidazolium.

Authors:  K Gietzen
Journal:  Biochem J       Date:  1983-12-15       Impact factor: 3.857

5.  P2 purinoceptor-mediated inositol phosphate formation in relation to cytoplasmic calcium in DDT1 MF-2 smooth muscle cells.

Authors:  B Hoiting; A Molleman; M Duin; A den Hertog; A Nelemans
Journal:  Eur J Pharmacol       Date:  1990-07-31       Impact factor: 4.432

6.  New, long-acting, potent bradykinin antagonists.

Authors:  F Lembeck; T Griesbacher; M Eckhardt; S Henke; G Breipohl; J Knolle
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

7.  Prostaglandins and muscarinic agonists induce cyclic AMP attenuation by two distinct mechanisms in the pregnant-rat myometrium. Interaction between cyclic AMP and Ca2+ signals.

Authors:  O Goureau; Z Tanfin; S Harbon
Journal:  Biochem J       Date:  1990-11-01       Impact factor: 3.857

8.  Bradykinin stimulates Ca2+ mobilization in NCB-20 cells leading to direct inhibition of adenylylcyclase. A novel mechanism for inhibition of cAMP production.

Authors:  C L Boyajian; A Garritsen; D M Cooper
Journal:  J Biol Chem       Date:  1991-03-15       Impact factor: 5.157

9.  Calcium and the alpha-action of catecholamines on guinea-pig taenia caeci.

Authors:  A Den Hertog
Journal:  J Physiol       Date:  1981-07       Impact factor: 5.182

10.  Regulation of histamine- and UTP-induced increases in Ins(1,4,5)P3, Ins (1,3,4,5)P4 and Ca2+ by cyclic AMP in DDT1 MF-2 cells.

Authors:  H Sipma; M Duin; B Hoiting; A den Hertog; A Nelemans
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

View more
  3 in total

1.  Turnover of bis-diphosphoinositol tetrakisphosphate in a smooth muscle cell line is regulated by beta2-adrenergic receptors through a cAMP-mediated, A-kinase-independent mechanism.

Authors:  S T Safrany; S B Shears
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

2.  O-GlcNAcylation homeostasis controlled by calcium influx channels regulates multiple myeloma dissemination.

Authors:  Parinya Samart; Sudjit Luanpitpong; Yon Rojanasakul; Surapol Issaragrisil
Journal:  J Exp Clin Cancer Res       Date:  2021-03-16

3.  Protein kinase Cε regulates nuclear translocation of extracellular signal-regulated kinase, which contributes to bradykinin-induced cyclooxygenase-2 expression.

Authors:  Rei Nakano; Taku Kitanaka; Shinichi Namba; Nanako Kitanaka; Hiroshi Sugiya
Journal:  Sci Rep       Date:  2018-06-04       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.